Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis

Allosteric interactions in the parathyroid hormone GPCR–arrestin complex formation

(2020) Lisa J. Clark et al.   Nature Chemical Biology

Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE

(2019) R. Eastell et al.   OSTEOPOROSIS INTERNATIONAL

Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability

(2019) E. V. McCloskey et al.   Archives of Osteoporosis

Ca2+ allostery in PTH-receptor signaling

(2019) Alex D. White et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis

(2019) N.B. Watts et al.   OSTEOPOROSIS INTERNATIONAL

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline

(2019) Richard Eastell et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial

(2019) John P. Bilezikian et al.   CURRENT MEDICAL RESEARCH AND OPINION

Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial

(2019) Benjamin Z Leder et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Abaloparatide Exerts Bone Anabolic Effects with Less Stimulation of Bone Resorption-Related Factors: A Comparison with Teriparatide

(2018) Akito Makino et al.   CALCIFIED TISSUE INTERNATIONAL

Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide

(2018) Jean-Yves Reginster et al.   CALCIFIED TISSUE INTERNATIONAL

ACTIVExtend: 24 Months of Alendronate after 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

(2018) Henry G Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis

(2018) Michael R. McClung et al.   MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY

The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years

(2018) A. Gilsenan et al.   OSTEOPOROSIS INTERNATIONAL

Parathyroid hormone(1–34) and its analogs differentially modulate osteoblastic Rankl expression via PKA/SIK2/SIK3 and PP1/PP2A–CRTC3 signaling

(2018) Florante R. Ricarte et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial

(2018) P.D. Miller et al.   BONE

Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis

(2017) Felicia Cosman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Osteoporosis-Related Health Services Utilization Following First Hip Fracture Among a Cohort of Privately-Insured Women in the United States, 2008-2014: An Observational Study

(2017) Catherine W Gillespie et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study

(2017) Eugene V McCloskey et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis

(2017) Felicia Cosman et al.   MAYO CLINIC PROCEEDINGS

Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption

(2017) N. Doyle et al.   OSTEOPOROSIS INTERNATIONAL

Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial

(2017) J. P. Bilezikian et al.   OSTEOPOROSIS INTERNATIONAL

Hip fracture trends in the United States, 2002 to 2015

(2017) E. Michael Lewiecki et al.   OSTEOPOROSIS INTERNATIONAL

Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1–34)

(2017) Jacquelin Jolette et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Pharmacological Therapy of Osteoporosis: A Systematic Current Review of Literature

(2017) Vito Pavone et al.   Frontiers in Pharmacology

Critical issues and current challenges in osteoporosis and fracture prevention. An overview of unmet needs

(2017) Willem F. Lems et al.   Therapeutic Advances in Musculoskeletal Disease

Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats

(2016) Hila Bahar et al.   CALCIFIED TISSUE INTERNATIONAL

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS — 2016

(2016) Pauline M. Camacho et al.   Endocrine Practice

Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling

(2016) Gary Hattersley et al.   ENDOCRINOLOGY

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis

(2016) Paul D. Miller et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors

(2016) Felicia Cosman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption

(2016) Aurore Varela et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Abaloparatide, a Human Parathyroid Hormone-Related Peptide Analog, on Bone Mineral Density in Postmenopausal Women with Osteoporosis

(2015) Benjamin Z. Leder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial

(2015) Benjamin Z Leder et al.   LANCET

Burden of Illness for Osteoporotic Fractures Compared With Other Serious Diseases Among Postmenopausal Women in the United States

(2015) Andrea Singer et al.   MAYO CLINIC PROCEEDINGS

Endosomal generation of cAMP in GPCR signaling

(2014) Jean-Pierre Vilardaga et al.   Nature Chemical Biology

Survival and Functional Outcomes After Hip Fracture Among Nursing Home Residents

(2014) Mark D. Neuman et al.   JAMA Internal Medicine

The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years

(2012) Elizabeth B Andrews et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Timing of Subsequent Fractures after an Initial Fracture

(2010) Tineke A. C. M. van Geel et al.   Current Osteoporosis Reports

Sustained cyclic AMP production by parathyroid hormone receptor endocytosis

(2009) Sébastien Ferrandon et al.   Nature Chemical Biology

Lack of Bone Neoplasms and Persistence of Bone Efficacy in Cynomolgus Macaques After Long-Term Treatment With Teriparatide [rhPTH(1-34)]*

(2008) John L Vahle et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Control of Bone Mass and Remodeling by PTH Receptor Signaling in Osteocytes

(2008) Charles A. O'Brien et al.   PLoS One

Altered Selectivity of Parathyroid Hormone (PTH) and PTH-Related Protein (PTHrP) for Distinct Conformations of the PTH/PTHrP Receptor

(2007) Thomas Dean et al.   MOLECULAR ENDOCRINOLOGY